We have been following emerging data on the efficacy of clinical vaccine trials against Neisseria gonorrhoeae, a ubiquitous sexually transmitted bacteria that can cause localised and systemic disease if left untreated. It can also be transmitted to neonates during birthing. Worldwide there has been a steady rise of gonorrhoea incidence and antibiotic resistance. In 2024 UK's Joint Committee on Vaccination and Immunisation recommended the off-label use of 4CMenB vaccine for the prevention of gonorrhoea infection in persons at high risk. Here we present the recent findings of the GoGoVax trial which presented at CROI 2026.

Links:

• Revisiting gonorrhoea prevention in the era of resistance and biomedical interventions
• Multicentre double-blind randomised placebo-controlled trial evaluating the efficacy of the meningococcal B vaccine, 4CMenB (Bexsero), against Neisseria gonorrhoeae infection in men who have sex with men: the GoGoVax study protocol
• GoGoVax | Kirby Institute
• GoGoVax dispels hopes for gonorrhoea vaccination

Participants:

Host: Ass Prof/Dr Fabiola Martin, Canberra Sexual Health Centre and Australian National University, Canberra, Australia Prof Kate Seib, Principal Research Leader and NHMRC Leadership Fellow, Institute for Biomedicine and Glycomics, Griffith University in Australia

Fiji has been reporting a significant rise in the incidence of Human immunodeficiency (HIV) and hepatitis C virus (HCV) over the last 3 years. Health officials estimate that about 9,000 people are living with HIV in Fiji today, nearly 1% of the population. A startling 2,016 new cases of HIV alone were reported in 2025, compared to 1,583 cases in 2024. Among people starting HIV treatment in 2024, 48% were people who inject drugs, highlighting the disproportionate impact on this group, and unsafe injecting drug use being the major driver of transmission, exposing urgent gaps in access to prevention and stigma-free care.

In addition, an estimated 59 infants were born with HIV in 2025, up from 31 in 2024, demonstrating the spread of HIV through sexual transmission and from birthing parent to child. There are limited epidemiological data available on HCV in Fiji but it's sharp rise has also been observed.

Links:

• Fiji strengthens its HIV response through evidence-based harm reduction
• Fiji’s HIV Epidemic Escalates
• Strengthening Fiji’s HIV response through shared expertise and regional collaboration

Participants:

Host: Ass Prof/Dr Fabiola Martin, Canberra Sexual Health Centre and Australian National University, Canberra, Australia

Dr Jason Mitchell, Lead of the SRH and HIV Unit at Ministry of Health and Medical Services and Chairperson of the National HIV Outbreak and Cluster Response Taskforce in Fiji